Latest Conference Articles

Optimal Frontline Hodgkin Lymphoma Treatment Requires Careful Consideration of Toxicities

Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.

Ongoing Research Aims to Solidify CAR T-Cell Therapy’s Place in Non-Hodgkin Lymphoma

CAR T-cell therapy has proven to be an effective treatment option in non-Hodgkin lymphoma subtypes, such as diffuse large B-cell lymphoma, and mantle cell lymphoma.

Checkpoint Inhibitor/TKI Combos Jump RCC Treatment to Next Level

Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.

Smarter Screening, Risk Assessments Are Key to Eliminating Racial Disparities in Breast Cancer Outcomes

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

With More At-Home Treatments Available, Importance of Medication Adherence Must Be Stressed

With more oral cancer therapies available, the importance of medication adherence and education must be recognized.

Knowledge of Biosimilars Becomes A Necessity in Oncology Nursing

Understanding the functionality and naming convention of biosimilars vs their biologic counterparts are important concepts to utilizing these agents in oncology, according to a presentation given by Teresa Knoop, MSN, RN, AOCN, during the 5th Annual School of Nursing Oncology Meeting.

Immunotherapy, Targeted Therapy, and Novel Strategies Progress Practice in GI Malignancies

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

CDK4/6 Inhibitors Improve OS, but Sequencing Strategies Continue to Form in HR+/HER2- Breast Cancer

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Pegram Points to Progress, Ongoing Efforts in Advanced HER2+ Breast Cancer

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

KRAS Inhibitors Reach New Milestones in NSCLC

Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

Dr. Arcila on Choosing Between Molecular Tests in Lung Cancer

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLC

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

Dr. Patel on the Potential With PARP/Immunotherapy Combos in NSCLC

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Understanding the Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Novel Vaccine Combos Represent a Promising Treatment Approach in Breast Cancer

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer.